HIVE
HIVE Digital Technologies Ltd.
There isn't enough reported data to score HIVE yet.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
HIVE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
HIVE's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIVE.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
HIVE PE Valuation
HIVE has no meaningful PE right now: it lost money over the past year.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
HIVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
HIVE has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HIVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.60 | -1433% |
| Q2 2026 | -$1.38 | -1162% |
| Q1 2026 | -$0.66 | -$0.44 |
| Q4 2025 | -$0.27 | -154% |
| Q3 2025 | $0.12 | -71% |
| Q2 2025 | $0.13 | -28% |
| Q1 2025 | -$0.22 | -238% |
| Q4 2024 | $0.50 | +$0.98 |
HIVE has swung to a loss: it lost $1.60 per share over the past year, after a profit the year before.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has the edge over HIVE on earnings, with more consistent year-over-year improvement.
HIVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.9M | -2.7% |
| Q2 2026 | $79.1M | +73% |
| Q1 2026 | $71.8M | +130% |
| Q4 2025 | $93.1M | +219% |
| Q3 2025 | $87.3M | +285% |
| Q2 2025 | $45.6M | +41% |
| Q1 2025 | $31.2M | -16% |
| Q4 2024 | $29.2M | -6.5% |
HIVE's revenue is growing: $85M last quarter, down 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -227% | -232 points |
| Q4 2025 | 18% | +25 points |
| Q3 2025 | -11% | +9.1 points |
| Q2 2025 | 78% | +132 points |
| Q1 2025 | 5.2% | -84 points |
| Q4 2024 | -7% | -30 points |
| Q3 2024 | -20% | -6.7 points |
| Q2 2024 | -54% | -68 points |
HIVE's operating margin was −227% last quarter, down 232 points from the same quarter a year ago, near the bottom of its range since 2019.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN has the edge over HIVE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
HIVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $858K | +$49.1M |
| Q2 2026 | -$10.7M | +$26.4M |
| Q1 2026 | -$21.8M | +$7.8M |
| Q4 2025 | -$9M | +$80.9M |
| Q3 2025 | -$48.2M | -$26.2M |
| Q2 2025 | -$37.1M | -$19.4M |
| Q1 2025 | -$29.5M | +$8.3M |
| Q4 2024 | -$89.9M | -$63.8M |
HIVE has the edge over IREN on cash flow, with more consistent year-over-year improvement.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
HIVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +7.8M shares |
| 1 year | +20% | +45.9M shares |
| 3 years | +222% | +189M shares |
| 5 years | +242% | +194M shares |
| Available history | +319% | +209M shares |
HIVE has 274M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has the edge over HIVE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
HIVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.0x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.3x | Very low |
| Q2 2024 | 0.0x | Very low |
HIVE has the edge over IREN on leverage, with a lower net debt burden relative to earnings.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
HIVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 6.1 | Oversold |
HIVE's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
HIVE PE vs Financial Services Sector
| Metric | HIVE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
HIVE has no meaningful PE right now: it lost money over the past year.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
HIVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 26% below |
| 20 week MA | $2.70 | 39% below |
| 50 week MA | $2.79 | 41% below |
| 100 week MA | $2.78 | 41% below |
| 200 week MA | $3.12 | 47% below |
HIVE is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has the edge over HIVE on trend strength, trading above more of its moving averages.
HIVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $8.30 | +1975% |
| 2021 | $8.30 | $15.3 | +84% |
| 2022 | $15.3 | $1.59 | -90% |
| 2023 | $1.59 | $4.53 | +185% |
| 2024 | $4.53 | $2.97 | -34% |
| 2025 | $2.97 | $2.72 | -8.4% |
| 2026 YTD | $2.72 | $1.65 | -39% |
HIVE has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.